Phase I trial of BEN301 injection for autoimmune diseases using CD4+ CAR+ Foxp3+ cells
Summary
The National Library of Medicine registered a new Phase I clinical trial (NCT07502859) on ClinicalTrials.gov evaluating BEN301 injection for autoimmune diseases using CD4+ CAR+ Foxp3+ cells. The trial is categorized as Phase I, indicating early-stage safety and dosing evaluation. No compliance deadlines or penalties are associated with this clinical trial registration.
What changed
A new clinical trial registration was posted to ClinicalTrials.gov for a Phase I study of BEN301 injection, an investigational cell therapy utilizing CD4+ CAR+ Foxp3+ cells for autoimmune diseases. The trial is sponsored by Peking University People's Hospital and registered under NCT07502859.
This is a routine registration notice with no required actions for compliance officers. Healthcare providers and clinical investigators interested in this cell therapy research can review the trial details on ClinicalTrials.gov. Patients with autoimmune diseases may discuss trial participation eligibility with their physicians.
Source document (simplified)
Show glossary
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.